Bayer invests in U.S. growth to get it through its big transitions

Carly Helfand

Plenty of 's peers are focusing their expansion efforts outside the , on emerging markets with more potential. But not the German pharma. Instead, it's working to boost its presence and brand in the U.S., beefing up operations in areas from marketing to research in what global innovation chief Kemal Malik recently told the AP was the "most important country for Bayer."

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS